The Republic of Ireland’s competitive corporate tax rate represents a ‘stability’ that may not be found in other economies, says IDA Ireland executive.
The US FDA has approved Merck & Co.’s bestseller Keytruda for two additional oncology indications – cervical cancer, and relapsed primary mediastinal large B-cell lymphoma.
Cellectis’ third gene-edited, ‘off-the-shelf’ CAR T-cell candidate is set to enter clinical development after the US FDA approved an IND application for UCART22.
The US FDA has issued a complete response letter to Amgen for its biosimilar version of Roche’s Herceptin, marking the agency’s third trastuzumab candidate rejection this year.
The European Commission has angered the biopharma industry by proposing to relax the rules detailing when companies can manufacture biosimilars and generics in the region.
TapImmune would consider a partnership deal with a major pharmaceutical firm in a non-Caucasian country, such as Japan or China, if “very compelling” from a financial standpoint, says CEO.
